NCT03817866 is a clinical trial of BRAHMS CgA II KRYPTOR in Gastric Neoplasms, sponsored by Brahms AG.

Who is sponsoring NCT03817866?

NCT03817866 is sponsored by Brahms AG.

What drugs are being tested in NCT03817866?

Interventions in NCT03817866: BRAHMS CgA II KRYPTOR.

What condition does NCT03817866 study?

NCT03817866 studies Gastric Neoplasms, Pancreatic Neoplasms, Small Intestinal Neoplasms, Colorectal Neoplasms.

Is NCT03817866 still recruiting?

NCT03817866 is currently completed. Last updated 20 December 2022.

Last reviewed 2022-12-20 · How we verify

NCT03817866

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chromogranin A as Blood Marker in Cancer Patients

Completed Last updated 20 December 2022

What this trial tests

trial testing BRAHMS CgA II KRYPTOR in Gastric Neoplasms in 175 participants. Completed in 14 December 2021.

Timeline

29 January 2019

Primary endpoint
14 December 2021

14 December 2021

Quick facts

Lead sponsor	Brahms AG
Status	Completed
Study type	OBSERVATIONAL
Enrollment	175
Start date	29 January 2019
Primary completion	14 December 2021
Estimated completion	14 December 2021
Sites	4 locations across United States, Germany

Drugs / interventions tested

BRAHMS CgA II KRYPTOR

Conditions studied

Gastric Neoplasms — all drugs for Gastric Neoplasms →
Pancreatic Neoplasms — all drugs for Pancreatic Neoplasms →
Small Intestinal Neoplasms — all drugs for Small Intestinal Neoplasms →
Colorectal Neoplasms — all drugs for Colorectal Neoplasms →

Sponsor

Brahms AG

Who can join

Adults 18 to 85, any sex, with Gastric Neoplasms or Pancreatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms that arise from enterochromaffin cells of the gastrointestinal (GI) tract and pancreas. They account for 50-70% of all incident NETs. Due to the lack of symptoms in the early stage of disease and the frequency of nonspecific GI symptoms, GEP-NETs are difficult to diagnose. Identification of effective biomarkers (such as Chromogranin A) to improve GEP-NET diagnosis, as well as to assess treatment efficacy, relapse and prognosis, is important for improving outcomes for patients with GEP-NETs. The purpose of this study is to validate the performance of Brahms (BRAHMS) Chromogranin A II Kryptor (KRYPTOR) assay to monitor the course of disease in patients with well-defined GEP-NETs.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Diagnostic biomarkers for pancreatic cancer: An update.
Yang M, Zhang CY. · · 2021 · cited 14× · PMID 34963749 · DOI 10.3748/wjg.v27.i45.7862
Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study.
Meng QH, Halfdanarson TR, Bornhorst JA, Jann H, et al · · 2024 · cited 2× · PMID 39453770 · DOI 10.1158/1078-0432.ccr-24-1875

Verify or expand the search:

Other recruiting trials for Gastric Neoplasms

Currently open trials in the same condition.

NCT06848400 — Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios · NA · recruiting
NCT05152147 — A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanc · Phase 3 · active not recruiting
NCT05551416 — The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer · recruiting
NCT01915225 — Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer · recruiting

Other Brahms AG trials

Trials by the same sponsor.

NCT05108883 — Risk Stratification Using Midregional Proadrenomedullin in the ED · NA · completed
NCT03770533 — Identifying Patients With Suspicion of Infection in the ED Who Have Low Disease Severity Using MR-proADM - Pilot Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03817866 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brahms AG
Last refreshed: 20 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03817866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing